Advancing Equity Through Early Detection, Genomic Innovation, and Collective Action

International Rare Disease Day 2026 serves as a critical reminder that rarity does not diminish impact. Although each rare disease affects a small number of individuals, collectively these conditions represent a major global health challenge requiring scientific commitment, policy prioritization, and equitable access to diagnostics and care.

Why Rare Diseases Demand Special Attention

An estimated 7,000 diseases are currently classified as rare. Despite their diversity, they share common and urgent challenges:

• Approximately 40% of patients experience at least one misdiagnosis, often leading to delayed or inappropriate treatment.
• Nearly 95% of known rare diseases lack curative therapy, leaving most patients to receive symptomatic management rather than treatment targeting the underlying cause.
• Around 80% of rare diseases are caused by genetic abnormalities, underscoring the importance of molecular diagnostics in establishing accurate diagnoses.

The diagnostic odyssey faced by patients with rare diseases often spans years. This delay not only affects clinical outcomes but also imposes significant psychological, social, and financial burdens on families and healthcare systems.

Rare Diseases in Indonesia: A Growing Public Health Concern

According to the World Health Organization (WHO), rare diseases remain underprioritized within national health programs in many developing countries, including Indonesia. This gap in policy focus presents unique challenges for a country characterized by extensive genetic diversity.

Indonesia’s large and heterogeneous population increases the likelihood of a significant cumulative incidence of rare diseases. The consequences extend beyond individual patients:

• Rare diseases contribute to approximately 35% of early childhood mortality.
• The economic burden of long-term therapy is substantial for both families and national health financing systems.

A representative example is Thalassemia, a hereditary blood disorder with high prevalence in certain populations. The lifetime direct and indirect costs, from birth to death, can reach approximately IDR 10 million per month per patient, creating profound socioeconomic strain. Beyond financial impact, Thalassemia illustrates the intergenerational nature of genetic disorders and the critical importance of preventive strategies.

Prevention and Early Detection: Strategic Imperatives

Given that the majority of rare diseases are genetic in origin, preventive approaches aimed at reducing the union of recessive mutations represent a key public health strategy. These efforts may include:

• Genetic screening programs
• Premarital counseling
• Prenatal diagnosis
• Comprehensive public education initiatives

Early identification and systematic registration of carriers enable:

• More comprehensive disease management
• Informed medical and reproductive decision-making
• Delivery of precision-based, targeted therapies when available

Such measures not only improve patient outcomes but also reduce long-term healthcare expenditures and societal burden.

The Role of Next-Generation Sequencing in Rare Disease Diagnosis

In recent years, Next-Generation Sequencing (NGS) technologies have transformed the diagnostic landscape of rare diseases. Compared with conventional diagnostic methods, NGS-based approaches, particularly Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) now dominate the rare disease diagnostic market due to their ability to:

• Simultaneously analyze thousands of genes
• Detect single nucleotide variants, insertions, deletions, and structural abnormalities
• Shorten the diagnostic journey for complex and atypical clinical presentations

WES and WGS have proven especially valuable in cases where traditional targeted testing fails to identify a clear etiology. By enabling comprehensive genomic interrogation, these technologies facilitate earlier, more precise diagnoses and open opportunities for personalized management strategies.

A Call to Action for 2026

International Rare Disease Day 2026 calls upon healthcare professionals, policymakers, researchers, and industry stakeholders to strengthen collaborative frameworks that prioritize:

• Expansion of genomic testing accessibility
• Integration of rare disease registries
• Development of targeted therapies
• Sustainable national strategies for prevention and early detection

Rare diseases may be individually uncommon, but collectively they represent a significant and addressable global health burden. Through genomic innovation, early detection, and coordinated policy action, we can move toward a future where patients with rare diseases receive timely diagnosis, equitable care, and renewed hope.

References:

1. ACOG. 2018. Modern Genetics in Obstetrics and Gynecology.
2. Fiorentino, F., Kokkali, G., Nuccitelli, A., Periklis, M., Serafini, S., Pantou, A., Proietti, C., Lazaros, L., Cisternino, R., Palaiologou, D., Mestichelli, M., Mitrakos, A., Pagano, I., & Pantos, K. (2025). O-271 Clinical application of Whole-Exome Sequencing (WES)-based Preimplantation Genetic Testing (PGT) for the assessment of embryo genetics and viability. Human Reproduction. https://doi.org/10.1093/humrep/deaf097.271.
3. Wu, T., Hu, X., Mo, M., Xu, S., Zhang, H., Geng, Q., & Zeng, Y. (2023). O-304 Whole-exome sequencing in women with reproductive failure is a potentially useful diagnostic test in clinical practice. Human Reproduction. https://doi.org/10.1093/humrep/dead093.368.
4. Patiño, L., Beau, I., Carlosama, C., Buitrago, J., González, R., Suárez, C., Patarroyo, M., Delemer, B., Young, J., Binart, N., & Laissue, P. (2017). New mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing. Human Reproduction, 32, 1512–1520. https://doi.org/10.1093/humrep/dex089.